Key result
Combined Cystatin C and HDL accurately identifies Alzheimer's disease and vascular dementia with ~0.87-0.90 AUC.
Why the study?
Whether plasma cystatin C and high-density lipoprotein levels can reliably distinguish dementia patients from healthy subjects and determine disease severity remains largely unknown.
Can plasma Cystatin C and HDL levels distinguish patients with Alzheimer's disease and vascular dementia from healthy subjects?
Cross-Sectional (n=133)
No
Can plasma Cystatin C and HDL levels distinguish patients with Alzheimer's disease and vascular dementia from healthy subjects?
Effect estimate: AUC 0.873 (95% CI 0.797-0.950)
p-value: p=<0.001
Plasma Cystatin C and HDL levels may serve as useful biomarkers for differentiating Alzheimer's disease and vascular dementia from healthy subjects.
Supports Cystatin C/HDL panels for dementia biomarker research; cross-sectional data leave clinical utility unproven.
Objectives Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer’s disease (AD) and vascular dementia (VaD). However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown. Methods We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls. The severity of dementia was determined based on the Schwab & England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental Activities of Daily Living (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski). Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects. Results We found that plasma Cys C levels were higher, but HDL levels were lower in AD and VaD patients respectively, compared to healthy control subjects. Yet, Cys C levels were highest among patients with VaD. Interestingly, plasma Cys C levels were significantly correlated with IADL Scale scores. In addition, the ROC curves for Cys C (AUC 0.816 for AD, AUC 0.841 for VaD) and HDL (AUC 0.800 for AD, AUC 0.731 for VaD) exhibited potential diagnostic value in distinguishing AD/VaD patients from healthy subjects. While the ROC curve for the combination of Cys C and HDL (AUC 0.873 for AD, AUC 0.897 for VaD) showed higher diagnostic accuracy in distinguishing AD/VaD patients from healthy subjects than the separate curves for each parameter. Conclusions Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) conducted a cross-sectional in Alzheimer's Disease and Vascular Dementia (n=133). Plasma Cystatin C and High-Density Lipoprotein vs. Healthy age-matched controls was evaluated on Diagnostic accuracy (AUC) of combined Cys C and HDL for distinguishing Alzheimer's disease from healthy subjects (AUC 0.873, 95% CI 0.797-0.950, p=<0.001). The combination of plasma Cystatin C and HDL demonstrated high diagnostic accuracy in distinguishing patients with Alzheimer's disease (AUC 0.873) and vascular dementia (AUC 0.897) from healthy subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: